Exrna Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 31-10-2024
- Paid Up Capital ₹ 0.50 M
as on 31-10-2024
- Company Age 3 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
About Exrna Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sushma Kumari, Vinay Tiwary, and Satyam serve as directors at the Company.
- CIN/LLPIN
U24239BR2021PLC055228
- Company No.
055228
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
22 Nov 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Exrna Therapeutics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sushma Kumari  | Director | 22-Nov-2021 | Current |
| Vinay Tiwary | Director | 22-Nov-2021 | Current |
| Satyam | Director | 22-Nov-2021 | Current |
Financial Performance of Exrna Therapeutics.
Exrna Therapeutics Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Exrna Therapeutics?
In 2023, Exrna Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vastu Vihar Biotech Private LimitedActive 10 years 9 monthsSushma Kumari, Vinay Tiwary and 1 more are mutual person
Technoculture Building Centre Private LimitedActive 22 years 9 monthsSushma Kumari and Vinay Tiwary are mutual person
Vastu Vihar Construction And Utility Services Private LimitedActive 17 years 10 monthsSushma Kumari and Vinay Tiwary are mutual person
Vastu Vihar Media Ventures Private LimitedActive 11 years 6 monthsSushma Kumari and Vinay Tiwary are mutual person
- Vastu Nano Construction Private LimitedActive 17 years 11 months
Sushma Kumari and Vinay Tiwary are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Exrna Therapeutics?
Exrna Therapeutics has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Exrna Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Exrna Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
